Dossier assessment

Emicizumab (haemophilia A) - Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A18-20
Last updated

Report documents

  1. Extract of dossier assessment

    Emicizumab (haemophilia A) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 131 kB, EN, not accessible
  2. Dossier assessment

    Emicizumab (haemophilia A) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 741 kB, DE, not accessible

Dossier assessment

Indication:

Routine prophylaxis of bleeding episodes in patients with haemophilia A with factor VIII inhibitors

Result of dossier assessment:

Added benefit not proven due to lack of suitable study data

Press releases

Haemophilia A and sialorrhoea: comparator therapies not implemented, added benefit not proven

Current standards of care were not implemented in studies

Additional information

Federal Joint Committee (G-BA)

2018-09-20 A G-BA decision was published.

G-BA documents on this decision

Project details

Project no.
A18-20
Commission
Commission awarded on 27.03.2018 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Haematology
Note

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Connected Projects

  1. Dossier assessment

    Emicizumab (haemophilia A) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A19-26
    Last updated

    Status: Commission completed

  2. Addendum

    Emicizumab (haemophilia A) - Addendum to Commission A18-20

    Project no.
    A18-49
    Last updated

    Status: Commission completed

  3. Dossier assessment

    Emicizumab (haemophilia A) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A23-10
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form